Related by context. All words. (Click for frequent words.) 76 HER2 positive 73 metastatic breast cancer 71 metastatic prostate cancer 70 NSCLC 70 ovarian cancer 69 metastatic renal cell carcinoma 68 HRPC 67 metastatic disease 67 colorectal cancer 67 metastatic colorectal cancer 67 hormone refractory prostate cancer 67 recurrent ovarian cancer 66 multiple myeloma 66 relapsed ovarian cancer 66 HER2 positive metastatic breast 66 advanced NSCLC 66 invasive breast cancer 66 metastatic melanoma 66 lapatinib 66 chronic lymphocytic leukemia CLL 65 metastatic cancer 65 medullary thyroid cancer 65 bone metastasis 65 malignant pleural mesothelioma 65 pancreatic NET 65 abiraterone 65 castration resistant prostate cancer 65 metastatic kidney 65 myeloma 65 metastatic colon cancer 65 breast cancers 64 epithelial ovarian cancer 64 brain metastases 64 basal cell carcinoma BCC 64 vandetanib 64 trabectedin 64 trastuzumab 64 breast cancer 64 indolent NHL 64 heavily pretreated 64 metastatic RCC 63 melanoma 63 bone metastases 63 malignant melanoma 63 gastrointestinal stromal tumors 63 axitinib 63 nonsmall cell lung cancer 63 localized prostate cancer 63 lupus nephritis 63 renal cell carcinoma 63 endometrial cancer 63 Taxotere ® 63 anastrozole 63 Hepatocellular Carcinoma HCC 63 colorectal cancers 63 prostate cancer CRPC 62 acute myelogenous leukemia AML 62 neoadjuvant therapy 62 seminoma 62 leukemia AML 62 prostate cancer 62 cetuximab 62 Herceptin 62 Herceptin trastuzumab 62 follicular lymphoma 62 YONDELIS 62 glioblastoma 62 tamoxifen therapy 62 CMV disease 62 gastrointestinal stromal tumor GIST 62 colorectal cancer CRC 62 HER2 overexpression 62 cell lung cancer 61 pancreatic adenocarcinoma 61 Tykerb 61 ovarian cancers 61 CLL 61 hormonal therapy 61 Irinotecan 61 HNSCC 61 breast tumors 61 chronic myeloid leukemia CML 61 operable breast cancer 61 mRCC 61 superficial bladder cancer 61 Torisel 61 lung tumors 61 prostate cancers 61 resistant ovarian cancer 61 GIST 61 relapsing remitting multiple sclerosis 61 tamoxifen 61 Bezielle 61 decitabine 61 adjuvant therapy 61 hormone receptor positive 61 hormone deprivation 61 prostate cancer HRPC 61 metastatic renal cell 61 trastuzumab Herceptin 61 hepatocellular cancer 61 pancreatic cancers 61 chemoradiation 61 cabazitaxel 61 recurrent NSCLC 61 gastric cancer 61 leukemia ALL 61 endometrial cancers 60 mCRC patients 60 IV melanoma 60 sunitinib 60 docetaxel chemotherapy 60 Malignant Melanoma 60 trastuzumab DM1 60 gastrointestinal stromal tumors GIST 60 solid tumors 60 B CLL 60 elacytarabine 60 Lapatinib 60 neuroendocrine tumors 60 cisplatin chemotherapy 60 aromatase inhibitor 60 gynecological cancers 60 mCRC 60 medically inoperable 60 vinorelbine 60 T DM1 60 pancreatic cancer 60 chemoradiotherapy 60 erlotinib 60 tumor shrinkage 60 sorafenib 60 Neoadjuvant 60 Trastuzumab 60 breast carcinoma 60 OncoVEX GM CSF 60 tumors 60 Zolinza 60 tumor recurrence 60 HCV infection 60 hormone refractory 60 IMGN# 60 AA amyloidosis 60 differentiated thyroid 60 docetaxel 60 Erlotinib 60 HER2 positive cancers 60 neoadjuvant chemotherapy 60 lung cancer 60 pancreatic neuroendocrine tumors 59 temozolomide 59 acute myeloid leukemia AML 59 Femara 59 systemic lupus erythematosus SLE 59 preoperative chemotherapy 59 dasatinib 59 Sutent 59 eribulin 59 relapsed MM 59 chlorambucil 59 disease progression 59 relapsed leukemia 59 bevacizumab Avastin 59 Acute Myelogenous Leukemia AML 59 cancers 59 TEMODAL 59 acute leukemias 59 tesmilifene 59 GnRH agonists 59 standard chemotherapy regimen 59 Amrubicin 59 olaparib 59 adjuvant chemotherapy 59 rheumatoid arthritis RA 59 biologic therapy 59 pomalidomide 59 cetuximab Erbitux 59 pertuzumab 59 eniluracil 59 metastatic gastric 59 tanespimycin 59 hepatocellular carcinoma 59 colon cancer 59 topotecan 59 recurrent prostate cancer 59 gefitinib 59 metastatic colorectal 59 EGFR mutation 59 Arranon 59 adult chronic ITP 59 stage IIIB 59 hepatocellular carcinoma HCC 59 advanced metastatic prostate 59 Halaven 59 gemcitabine chemotherapy 59 relapsed SCLC 59 anticancer therapy 59 TORISEL 59 ALCL 59 metastatic 59 Hodgkin lymphoma HL 59 prostate cancer mCRPC 59 recurrent glioblastoma 59 IV NSCLC 59 enzastaurin 59 angiogenesis inhibitor 59 gynecologic cancers 59 Metastatic breast cancer 59 Gleevec imatinib 59 PARP inhibitors 59 chemotherapy 59 cytotoxic therapy 59 erlotinib Tarceva ® 59 lung cancers 58 castrate resistant prostate cancer 58 phenoxodiol 58 carcinoid cancer 58 hereditary breast cancer 58 liver cancer 58 DLBCL 58 standard chemotherapy regimens 58 urothelial bladder cancer 58 Glioblastoma Multiforme 58 metastatic pancreatic cancer 58 endometriosis 58 temsirolimus 58 trastuzumab Herceptin ® 58 cancer 58 Neulasta ® 58 ixabepilone 58 fallopian tube carcinoma 58 hormonal therapies 58 SUTENT 58 azacitidine 58 pre cancerous lesions 58 refractory ovarian cancer 58 PLX# 58 Taxotere 58 alvespimycin 58 cervical lesions 58 taxane therapy 58 sorafenib Nexavar 58 tocilizumab 58 cisplatin 58 liver metastases 58 Taxotere R 58 myelodysplastic syndrome MDS 58 unresectable stage 58 ASA# 58 relapsed refractory multiple myeloma 58 IV metastatic melanoma 58 letrozole 58 phase IIb clinical 58 prostate tumors 58 taxane chemotherapy 58 Alessandro Riva 58 EGFR inhibitors 58 metastatic cancers 58 Gleevec resistant 58 idiopathic pulmonary fibrosis IPF 58 obatoclax 58 malignancies 58 leukemia CLL 58 nonmelanoma skin cancers 58 chemotherapy regimen 58 Multiple Myeloma 58 IMA# 58 chronic ITP patients 58 bortezomib 58 VIDAZA 58 relapsing remitting MS 58 exemestane 58 HER2 + 58 HER2 58 Tarceva erlotinib 58 bendamustine 58 non squamous NSCLC 58 Xeloda 58 relapsed multiple myeloma 58 IRESSA 58 SHPT 58 LHRH agonists 58 ductal cancer 58 acute myeloid leukemia 58 breast cancer recurrence 58 stage IIIB IV 58 relapsing MS 58 SCCHN 58 luteinizing hormone releasing 58 chronic myeloid leukemia 58 metastatic castration resistant 58 panitumumab Vectibix 58 abiraterone acetate 58 XELOX 58 Jevtana 58 non metastatic osteosarcoma 58 Chronic Myeloid Leukemia 58 Vandetanib 58 ganetespib 58 Dasatinib 58 irinotecan chemotherapy 58 sunitinib malate 57 androgen deprivation 57 bladder cancer 57 FSAD 57 gemcitabine 57 chemotherapy regimens 57 pegylated liposomal doxorubicin 57 precancerous cervical lesions 57 recurrent glioblastoma multiforme 57 entecavir 57 epithelial ovarian 57 Acute myeloid leukemia 57 platinum refractory 57 vaginal atrophy 57 afatinib 57 refractory multiple myeloma 57 ErbB2 positive 57 IV malignant melanoma 57 Pixantrone 57 pleural mesothelioma 57 myelofibrosis 57 cervical cancer 57 adjuvant radiation 57 advanced HER2 positive 57 sapacitabine 57 androgen independent 57 clinically localized prostate 57 depsipeptide 57 Testicular cancer 57 relapsing multiple sclerosis 57 Fludara 57 erlotinib Tarceva 57 metastatic malignant melanoma 57 Avastin bevacizumab 57 alkylating agent 57 HCV infected 57 BRAF V# mutation 57 eosinophilic asthma 57 entinostat 57 SNT MC# 57 prostate adenocarcinoma 57 Theratope 57 Hycamtin 57 FOLOTYN 57 Renal Cell Carcinoma RCC 57 refractory CTCL 57 Docetaxel 57 Afinitor 57 Proxinium TM 57 ovarian carcinoma 57 bevacizumab 57 Faslodex 57 lymphoma CTCL 57 Velcade bortezomib 57 refractory metastatic colorectal cancer 57 atypical hyperplasia 57 vascular disrupting agent 57 grade gliomas 57 adenocarcinoma 57 lymphomas 57 anti angiogenic therapy 57 Anthracycline 57 breast irradiation 57 imatinib Gleevec 57 Revlimid lenalidomide 57 GvHD 57 BZL# 57 metastatic CRC 57 SJIA 57 invasive candidiasis 57 hematological cancers 57 chemotherapeutic regimens 57 Nexavar sorafenib 57 Metastatic Colorectal Cancer 57 BCIRG 57 systemic lupus erythematosus 57 paclitaxel Taxol 57 EBRT 57 tyrosine kinase inhibitor 57 Acute Myeloid Leukemia AML 57 EGFR mutations 57 aromatase inhibitors 57 HER2 positive tumors 57 recurrent ovarian 57 CoFactor 57 lupus 57 GISTs 57 Acute Myeloid Leukemia 57 sarcoma 57 refractory AML 57 receptor tyrosine kinase inhibitor 57 vismodegib 57 pegfilgrastim 57 pazopanib 57 Rituxan rituximab 57 capecitabine 57 colorectal liver metastases 57 Quinamed 57 Acute Myeloid Leukaemia AML 57 Cloretazine 57 squamous cell lung cancer 57 FOLFOX4 57 metastatic hormone refractory 57 Rituximab 57 chemotherapy cisplatin 57 Glioblastoma 57 endocrine therapy 57 soft tissue sarcomas 57 Waldenstrom macroglobulinemia 57 efalizumab 57 KRAS status 57 elesclomol 57 Hydroxyurea 57 cytoreduction 57 metastatic castrate resistant 57 lumiliximab 57 KRAS mutations occur 57 anthracyclines 57 leukemia APL 57 metastatic lung cancer 57 acute promyelocytic leukemia 57 diagnosed multiple myeloma 57 Follicular Lymphoma 56 CHOP chemotherapy 56 hematologic malignancies 56 imatinib 56 chemopreventive agent 56 EGFR TKI 56 pegylated interferon alpha 56 Cetuximab 56 CYT# potent vascular disrupting 56 Non Hodgkin Lymphoma 56 cervical carcinoma 56 androgen deprivation therapy 56 Talabostat 56 Doxil ® 56 Adjuvant chemotherapy 56 postmenopausal osteoporosis 56 carcinoid 56 Annamycin 56 ZOLINZA 56 Carcinoma 56 Androgen deprivation therapy 56 invasive cervical cancer 56 regorafenib 56 prostate cancer AIPC 56 Alemtuzumab 56 recurrent colorectal cancer 56 Prostate cancer 56 anthracycline taxane 56 metastatic bladder 56 LHRH agonist 56 imatinib Gleevec ® 56 chemotherapeutic agent 56 Imatinib 56 tyrosine kinase inhibitors 56 metastases 56 glioblastoma multiforme GBM 56 cutaneous T cell 56 BRAF inhibitor 56 Amigal 56 prostate cancer CaP 56 Taxotere docetaxel 56 imatinib therapy 56 goserelin 56 Myelofibrosis 56 Tavocept 56 figitumumab 56 Xeloda capecitabine 56 LHRH antagonists 56 aromatase inhibitors AIs 56 HER2 positive breast 56 nilotinib 56 LY# [003] 56 oral ridaforolimus 56 ductal breast cancer 56 TroVax ® 56 peritoneal cancer 56 vinca alkaloids 56 neoplasia 56 rectal cancer 56 rindopepimut 56 Carboplatin 56 pCR 56 Sym# 56 lobular cancer 56 vemurafenib 56 belinostat 56 DMARD 56 PROSTVAC TM 56 endometrial hyperplasia 56 myelofibrosis polycythemia vera 56 Xanafide 56 BRCA mutation carriers 56 anti TNF 56 REVLIMID 56 iniparib 56 multiple myeloma MM 56 ovarian tumors 56 metastatic HER2 positive 56 anti leukemic 56 voreloxin 56 BRCA mutations 56 HuMax EGFr 56 pemetrexed 56 bevacizumab Avastin ® 56 Avastin 56 Myelodysplastic syndromes MDS 56 BRCA deficient 56 lung adenocarcinoma 56 Bevacizumab 56 lapatinib Tykerb 56 ependymoma 56 carcinoma 56 Dacogen injection 56 Ceflatonin 56 Cytoxan 56 anti androgen 56 Metastatic 56 Anastrozole 56 chronic myelogenous leukemia CML 56 IMC A# 56 neoadjuvant treatment 56 Pertuzumab 56 Cutaneous T 56 FTY# 56 hepatitis C HCV 56 Cell Lymphoma CTCL 56 lobular carcinoma 56 EGFR tyrosine kinase inhibitors 56 secondary hyperparathyroidism 56 locoregional 56 HuMax CD4 56 Lilly Gemzar 56 Metastatic Breast Cancer 56 ELACYT 56 myelodysplastic syndromes MDS 56 FOLFIRI 56 zoledronic acid 56 Laquinimod 56 Gefitinib 56 gefitinib Iressa 56 epirubicin 56 Diabetic Macular Edema 56 Abiraterone acetate 56 refractory angina 56 autoantibody positive 56 Li Fraumeni Syndrome 56 AVODART 56 Metastatic Prostate Cancer 56 Natalizumab 56 carcinoid tumors 56 bicalutamide 56 tyrosine kinase inhibitors TKIs 56 anti EGFR antibody 56 cutaneous melanoma 56 molecularly targeted 56 Tamoxifen 56 lenalidomide Revlimid R 56 TREANDA 56 mycophenolate mofetil 56 seliciclib 56 TTF Therapy 56 Folotyn 56 Vectibix 56 SAR# [004] 56 glufosfamide 56 cytogenetic responses 56 Hodgkin Lymphoma 56 dasatinib Sprycel 56 HER2 negative 56 metastatic GIST 56 bladder cancers 56 Cell Lung Cancer 55 Cisplatin 55 metastatic sarcomas 55 distant metastasis 55 angiogenesis inhibition 55 gynecologic cancer 55 KRAS mutation 55 biliary tract cancer 55 glioblastomas 55 Everolimus 55 Gemcitabine 55 estrogen therapy 55 CIN3 55 Femara letrozole 55 dasatinib Sprycel ® 55 trastuzumab emtansine 55 perifosine 55 Tarceva 55 recurrent GBM 55 docetaxel Taxotere 55 malignancy 55 virologic failure 55 overactive bladder OAB 55 relapsed GBM 55 fulvestrant 55 tumors GIST 55 Chronic Lymphocytic Leukemia 55 Bortezomib 55 nab paclitaxel 55 nucleoside analog 55 Campath alemtuzumab 55 Xelox 55 Aurora kinase 55 Aplidin 55 panitumumab 55 IRX 2 55 EGFr 55 vorinostat 55 assessing T DM1 55 cisplatin resistant 55 Gleevec imatinib mesylate 55 eflornithine 55 DCIS 55 medulloblastoma 55 PXD# 55 HGS ETR1 55 ofatumumab 55 Yervoy 55 PSADT 55 estrogen receptor positive 55 CaP 55 APTIVUS r 55 dacarbazine 55 relapsed refractory 55 LHRH receptor positive 55 squamous cell 55 mycosis fungoides 55 basal cell carcinomas 55 advanced hepatocellular carcinoma 55 mapatumumab 55 refractory CLL 55 Hepatocellular Carcinoma 55 GBM tumors 55 thymalfasin 55 Fludara ® 55 Acute Radiation Syndrome ARS 55 squamous cell carcinoma SCC 55 estrogen receptor negative 55 Pazopanib 55 myeloproliferative disorders 55 Chronic Lymphocytic Leukemia CLL 55 Gleevec 55 symptomatic BPH 55 familial ALS 55 Sunitinib 55 ADPKD 55 Pancreatic Cancer 55 rituximab 55 EndoTAG TM -1 55 Ozarelix 55 GIST tumors 55 dirucotide 55 liposomal doxorubicin 55 Symadex 55 post menopausal osteoporosis 55 neoadjuvant 55 Lung cancer 55 pelvic malignancies 55 Hormone Refractory Prostate Cancer 55 Phase #/#a trial 55 renal carcinoma 55 Mantle Cell Lymphoma 55 heterozygous FH 55 ONCONASE 55 mitoxantrone 55 radiation therapy SBRT 55 Intravenous CP 55 Abiraterone 55 soft tissue sarcoma 55 melanomas 55 invasive lobular carcinoma 55 OMAPRO 55 myelodysplastic syndromes 55 ToGA 55 endocrine therapies 55 histologies 55 Advexin 55 severe sepsis 55 forodesine 55 distant metastases 55 hormone therapy 55 ponatinib 55 lymphoma 55 palifosfamide 55 chronic ITP 55 chlamydial infection 55 pralatrexate 55 antibody MAb 55 Xyotax 55 squamous cell cancer 55 CYC# 55 ovarian lung 55 uterine fibroids 55 cinacalcet 55 axillary dissection 55 Cholangiocarcinoma 55 hematological malignancy 55 pan HDAC inhibitor 55 GnRH agonist 55 Decitabine 55 unresectable liver cancer 55 BRAF mutation 55 Ilaris 55 malignant lymphoma 55 BRAF inhibitors 55 hypophosphatasia 55 Ovarian cancer 55 Prodarsan ® 55 Targretin 55 AA Amyloidosis 55 Sutent sunitinib 55 hypoparathyroidism 55 docetaxel Taxotere ® 55 advanced epithelial ovarian 55 sentinel lymph node biopsy 55 MDV# 55 recurrent glioma 55 basal cell carcinoma 55 microwave hyperthermia 55 gastrointestinal cancers 55 endometrial carcinoma 55 T#I [002] 55 nonhormonal 55 chronic lymphocytic leukemia 55 carboplatin paclitaxel 55 ER CHOP 55 romiplostim 55 CR# vcMMAE 55 severe psoriasis 55 heavily pretreated patients 55 complete cytogenetic response 55 antitumor effect 55 Barrett esophagus 55 cutaneous squamous cell carcinoma 55 crizotinib 55 sorafenib Nexavar ® 55 idarubicin 55 relapsing remitting 55 galiximab 55 adalimumab 55 haematological cancers 55 metastatic lesions 55 interferon beta 55 AEG# 55 adalimumab Humira 55 cilengitide 55 TKI therapy 55 oral fludarabine 55 chemotherapeutic regimen 55 BCG refractory 54 benign prostatic hyperplasia BPH 54 severe oral mucositis 54 AVASTIN 54 FASLODEX 54 SERCA2a 54 Cabazitaxel 54 PAOD 54 relapsing remitting MS RRMS 54 complete cytogenetic 54 capecitabine Xeloda 54 LUX Lung 54 KRAS mutant tumors 54 castration resistant 54 dacetuzumab 54 candidemia 54 clofarabine 54 MabThera rituximab 54 irinotecan 54 interferon IFN 54 dacarbazine chemotherapy 54 Aflibercept 54 Her2 54 EGFR mutation positive 54 recurrent metastatic 54 CTCL 54 osteoporotic fractures 54 TheraSphere 54 cardiotoxicity 54 refractory prostate cancer 54 trabedersen 54 carfilzomib 54 PEGylated interferon beta 1a 54 5FU 54 K ras mutations 54 evaluating tivozanib 54 Azedra 54 glioma 54 Evoltra TM 54 Cushing Syndrome 54 estramustine 54 Myelodysplastic Syndrome MDS 54 CINV 54 cervical dysplasia 54 INCB# [001] 54 systemic ALCL 54 amrubicin 54 carboplatin 54 indolent lymphomas 54 sorafenib tablets 54 XGEVA 54 cranial radiation 54 TACE 54 gastrointestinal stromal tumor 54 paclitaxel Taxol ® 54 myelofibrosis MF 54 RoACTEMRA 54 radiation sensitizer 54 XL# SAR# 54 noninfectious uveitis 54 Azacitidine 54 ankylosing spondylitis AS 54 Ophena 54 BEXXAR 54 protease inhibitor PI 54 pancreatic carcinoma 54 nonalcoholic steatohepatitis NASH 54 Temsirolimus 54 paclitaxel chemotherapy 54 OPAXIO 54 metastatic ovarian cancer 54 anticancer agents 54 unresectable 54 pegylated liposomal doxorubicin PLD 54 testicular cancers 54 hormone therapy estrogen 54 KRAS wild 54 Etanercept 54 gastric cancers 54 EOquin TM 54 BAY #-# 54 Median survival 54 exemestane Aromasin 54 Kit CD# positive 54 bowel cancer 54 colorectal tumors 54 Newly Diagnosed Multiple Myeloma 54 mTOR inhibitor 54 adjuvant radiotherapy 54 VPRIV 54 basal cell nevus syndrome 54 Folfox 54 PROSTVAC ® 54 rFIXFc 54 AGILECT R 54 gliomas 54 uterine cancers 54 tumor histology 54 interferon alfa 54 serous ovarian cancer 54 precancerous lesions 54 lymphoid malignancies 54 phase IIb trial 54 LQTS 54 vasomotor symptoms 54 Hodgkin lymphoma NHL 54 bladder carcinoma 54 cediranib 54 nonmelanoma skin cancer 54 EFAPROXYN 54 CBLC# 54 Breast cancer 54 Advaxis Phase 54 TAXOTERE R 54 Erbitux cetuximab 54 AP# [003] 54 Metastatic melanoma 54 prednisone prednisolone 54 DFMO 54 AMN# [001] 54 Tyrima 54 COPD 54 mutated KRAS gene 54 Allovectin 7 ® 54 IMC #B 54 Capecitabine 54 pre menopausal 54 MGd 54 Pemetrexed 54 breast ovarian 54 zanolimumab 54 non Hodgkin lymphoma 54 antiestrogen 54 anticancer compound 54 letrozole Femara 54 liver fibrosis 54 rectal cancers 54 metastatic CRPC 54 Novartis Gleevec 54 squamous cell carcinoma 54 refractory gout 54 thalidomide Thalomid 54 infusional 5-FU/LV 54 Ophena TM 54 Cristofanilli 54 PROSTVAC VF 54 endostatin 54 hereditary antithrombin deficiency 54 invasive aspergillosis 54 abatacept 54 neuroendocrine cancers 54 cetuximab Erbitux ® 54 recurrent VTE 54 uveal melanoma 54 raltegravir 54 methotrexate therapy 54 TOCOSOL Paclitaxel 54 systemic fungal infections 54 5-fluorouracil/leucovorin 54 Evoltra ® 54 velafermin 54 nonmetastatic 54 registrational 54 EndoTAGTM 1 54 taxanes 54 bortezomib Velcade 54 osteosarcoma 54 non hodgkin lymphoma 54 palliative radiotherapy 54 non Hodgkin lymphomas 54 opioid induced constipation OIC 54 acute ischemic stroke 54 5 Fluorouracil 54 CMV infection 54 rFVIIIFc 54 ovarian 54 Chronic lymphocytic leukemia 54 T#I mutation 54 octreotide LAR 54 miglustat 54 tumor progression 54 lung metastasis 54 peritoneal carcinomatosis 54 Epratuzumab 54 CALGB # [001] 54 PCNSL 54 darapladib 54 ThermoDox 54 HBV infection 54 colorectal carcinoma 54 OHR/AVR# 54 metastatic malignant 54 aflibercept 54 Denosumab 54 Advanced Melanoma 54 haematological malignancies 54 juvenile idiopathic arthritis 54 chemotherapies 54 Sorafenib 54 Mepact 54 AVOREN 54 MyVax R 54 systemic scleroderma 54 NNRTIs 54 ALK inhibitor 54 colorectal lung 54 systemic lupus 54 myeloproliferative diseases 54 grade cervical intraepithelial 54 daunorubicin 54 Pap smear screening 54 xenograft models 54 velaglucerase alfa 54 basiliximab 54 hepatitis C genotype 54 thyroid cancer 54 oral mucositis 54 imatinib resistant 54 refractory chronic myeloid 54 dose cohorts 54 HGS# 54 virological failure 54 DMARD therapy 54 cancer mCRC 54 PSMA ADC 54 nasopharyngeal carcinoma 54 Panitumumab 54 Golimumab 54 gynecological cancer 54 leukaemias 54 DAPT 54 Xcytrin 54 mTOR inhibitors 54 indibulin 54 Pralatrexate 54 S. aureus infections 54 Pancreatic cancer 54 DCVax Brain 54 Virulizin R 54 free survival PFS 54 Paraplatin ® 54 protein kinase inhibitor 54 Glioblastoma Multiforme GBM 54 cytotoxic chemotherapy 54 fludarabine 54 glioblastoma tumors